Laurion Capital Management’s Arcus Biosciences RCUS Stock Holding History

Laurion Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-20,263	Closed	-$310K	–	375
2024 Q3	$310K	Sell	20,263 -416,270	-95%	-$6.56M	﹤0.01%	229
2024 Q2	$6.65M	Sell	436,533 -110,941	-20%	-$1.79M	0.08%	140
2024 Q1	$10.3M	Buy	+547,474	New	+$9.47M	0.09%	187
2022 Q2	–	Sell	-181,244	Closed	-$5.72M	–	659
2022 Q1	$5.72M	Buy	+181,244	New	+$6.07M	0.07%	154
2018 Q3	–	Sell	-60,000	Closed	-$734K	–	1493
2018 Q2	$734K	Hold	60,000	–	–	0.01%	872
2018 Q1	$926K	Buy	+60,000	New	+$999K	0.01%	855

Other funds holding RCUS

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Laurion Capital Management's RCUS Position: Q4 2024 in Review

Laurion Capital Management sold out of Arcus Biosciences (RCUS) in Q4 2024, closing a stake of 20,263 shares — an estimated $310K sold.

Laurion Capital Management first reported a position in RCUS in Q1 2018 and held it in 6 quarters. The position peaked at $10.3M in Q1 2024. 186 funds tracked by Wall St. Rank hold RCUS as of Q4 2024.

Laurion Capital Management reported no remaining Arcus Biosciences position as of Q4 2024 after selling out during the quarter.
Laurion Capital Management sold 20,263 Arcus Biosciences shares in Q4 2024, an estimated $310K.
Laurion Capital Management first reported a position in Arcus Biosciences in Q1 2018 and held it in 6 quarters.
Laurion Capital Management's Arcus Biosciences position peaked at $10.3M in Q1 2024.
186 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2024.

Based on Laurion Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.